

Neoadjuvant Immunotherapy in MSI-H Rectal Cancer

Azza Darwish

Ass.Prof of Clinical Oncology
Faculty of Medicine
University of Alexandria

Declaration of interest

- **Honoraria for lectures and advisory boards** : MSD, Pfizer, Lilly, Novartis, Jansen, Astra, Zeneca

Rectal Cancer

- Therapy for locally advanced rectal cancer include radiotherapy, chemotherapy and surgery
- While cure is frequently achieved , radiotherapy and surgery have life-long consequences

QoL impairment after tri-modality therapy


- **Colostomy**
- **Faecal incontinence**
- **Infertility**
- **Sexual dysfunction**
- **Urinary dysfunction**

Rectal Cancer: Mismatch repair deficient (dMMR/MSI)

About 5-10% of all rectal cancers

Less sensitive to chemotherapy

Rectal cancer treated with total neoadjuvant therapy
chemotherapy and chemoRT followed by TME



MMRd/MSI


Outcome	No. of patients (%)	
	dMMR	pMMR
FOLFOX as initial treatment	<i>n</i> = 21	<i>n</i> = 63
Progression of disease	6 (29)	0
Response or stable disease	15 (71)	63 (100)
Chemoradiation as initial treatment	<i>n</i> = 16	<i>n</i> = 48
Progression of disease	0	0
Complete pathologic response	2 (13)	8 (17)

dMMR/MSI mCRC sensitive to ICB in metastatic
disease

Rectal Cancer: Mismatch repair deficient (dMMR/MSI)

About 5-10% of all rectal cancers

Less sensitive to chemotherapy



MMRd/MSI

Rectal cancer treated with total neoadjuvant therapy
chemotherapy and chemoRT followed by TME

Outcome	No. of patients (%)	
	dMMR	pMMR
FOLFOX as initial treatment	<i>n</i> = 21	<i>n</i> = 63
Progression of disease	6 (29)	0
Response or stable disease	15 (71)	63 (100)
Chemoradiation as initial treatment	<i>n</i> = 16	<i>n</i> = 48
Progression of disease	0	0
Complete pathologic response	2 (13)	8 (17)


dMMR/MSI mCRC sensitive to ICB in metastatic
disease

Rectal Cancer: Mismatch repair deficient (dMMR/MSI)

About 5-10% of all rectal cancers

Less sensitive to chemotherapy

Rectal cancer treated with total neoadjuvant therapy
chemotherapy and chemoRT followed by TME




MMRd/MSI

Outcome	No. of patients (%)	
	dMMR	pMMR
FOLFOX as initial treatment	<i>n</i> = 21	<i>n</i> = 63
Progression of disease	6 (29)	0
Response or stable disease	15 (71)	63 (100)
Chemoradiation as initial treatment	<i>n</i> = 16	<i>n</i> = 48
Progression of disease	0	0
Complete pathologic response	2 (13)	8 (17)

dMMR/MSI mCRC sensitive to ICB in metastatic disease

Microsatellite Instability/Mismatch Repair Deficiency in Cancer

3



Signaling Mechanism of PD-1 and PD-L1 and Inhibition of PD-1 Signaling in Microsatellite-Instability-High Cancers.

MHC1 denotes major histocompatibility complex 1.

Table 1. Immune checkpoint inhibitors in MSI/dMMR metastatic colorectal cancer.

Clinical Trials	Prior Systemic Treatment	n	CR (%)	PR (%)	SD (%)	PD (%)	NE (%)	1-Year PFS Rate (%)	1-Year OS Rate (%)	2-Year PFS Rate (%)	2-Year OS Rate (%)	Median Follow-Up (Months)
Keynote-016 [11]												
Pembrolizumab	≥1	28	11	46	32	4	7	-	-	-	-	8.7
Keynote-164 [12-14]												
Pembrolizumab, cohort A	≥2	61	3	30	18	46	3	34	72	31	55	31
Pembrolizumab, cohort B	≥1	63	8	25	24	40	3	41	76	37	63	24
CheckMate-142 [15-18]												
Nivolumab	≥1	74	9	24	31	31	5	44	-	-	-	21
Nivolumab + Ipilimumab	≥1	119	6	52	28	12	3	71	85	60	74	25.4
Nivolumab + Ipilimumab	0	45	13	56	16	13	2	77	83	74	79	29.0
NIPICOL [19]												
Nivolumab + Ipilimumab	≥2	57	19	40	30	5	3	73	84	-	-	18.1
CD-ON-MED14736-1108 [20]												
Durvalumab	≥1	36		22	-	-	-	38			54	29
NCT02227667 [20]												
Durvalumab	≥1	11		27	-	-	-	36				30
GARNET [21]												
Dostarlimab	≥1	69		36	-	-	-	-	-	-	-	-

Neoadjuvant immunotherapy – pros

- Response rates to immunotherapy higher in early vs advanced disease
 - Better outcome with neoadjuvant vs adjuvant (melanoma)
- Improved surgical outcomes - less extensive surgery / complete omission of surgery
- Inform on prognosis – guide (neo-)adjuvant therapy


- Recent data in MSI-H/dMMR locally advanced rectal cancer
 - Dostarlimab in MSI-H locally advanced rectal cancer (Cercek)
 - Sintilimab in MSI-H locally advanced rectal cancer (Chen)
 - Toripalimab +/- celecoxib in MSI-H localized CRC (Hu)
 - NICHE, NICHE-2 in MSI-H localized colon cancer (Chalabi)
 - Pembrolizumab in MSI-H localized solid tumors (Ludford)

Hypothesis:

In mismatch repair deficient rectal cancer, PD-1 blockade may be able to either:

- a) replace chemotherapy
- b) replace chemo *and* radiation therapy
- c) replace chemo *and* radiation, *and* surgery

MSKCC study



Patient population: Stage II and III mismatch repair deficient rectal cancer

Target Enrollment: 30 subjects

Study Design: Simon's two stage minimax design

Response Criteria

Overall response

Rectal MRI and endoscopic exam graded as stable disease (SD), partial response (PR), near complete response (nCR) and complete response (CR)

Clinical complete response (cCR)

Endoscopic exam:

- Visual disappearance of the rectal primary
- Normal digital rectal exam

Rectal MRI

- Lack of signal at DWI with scar on T2WI (DWI volume = 0)
- Each target lymph node must have decreased short axis to $<0.5\text{cm}$

Patient Demographics	
	N (%)
Female Sex	28 (58)
Median Age (range)	51 (26,78)
Race	
White	37 (77)
Asian	5(10)
Black	6 (13)
Non Hispanic/Latino	42 (85)
Hispanic/Latino	6 (13)
Tumor Stage	
T 0/1/2	10 (21)
T 3	23 (48)
T 4	15 (31)
N +	41 (85)
Median Distance from anal verge (cm)	5.1 (0, 14.8)

Patient Demographics	
	N (%)
Female Sex	28 (58)
Median Age (range)	51 (26,78)
Race	
White	37 (77)
Asian	5(10)
Black	6 (13)
Non Hispanic/Latino	42 (85)
Hispanic/Latino	6 (13)
Tumor Stage	
T 0/1/2	10 (21)
T 3	23 (48)
T 4	15 (31)
N +	41 (85)
Median Distance from anal verge (cm)	5.1 (0, 14.8)

Individual response to PD-1 blockade with dostarlimab


ID	Age	T stage	N stage	FU Months	Overall response
1	38	T4	N+	23.8	CR
2	30	T3	N+	20.5	CR
3	61	T1/2	N+	20.6	CR
4	28	T4	N+	20.5	CR
5	53	T1/2	N+	9.1	CR
6	77	T1/2	N+	11.0	CR
7	77	T1/2	N+	8.7	CR
8	55	T3	N+	5.0	CR
9	68	T3	N+	4.9	CR
10	78	T3	N-	1.7	CR
11	55	T3	N+	4.7	CR
12	27	T3	N+	4.4	CR
13	26	T3	N+	0.8	CR
14	43	T3	N+	0.7	CR

----- Single centre study

No observed $\geq$ Grade 3 toxicity


Individual response to PD-1 blockade with dostarlimab


ID	Age	T stage	N stage	FU Months	Overall response
1	38	T4	N+	23.8	CR
2	30	T3	N+	20.5	CR
3	61	T1/2	N+	20.6	CR
4	28	T4	N+	20.5	CR
5	53	T1/2	N+	9.1	CR
6	77	T1/2	N+	11.0	CR
7	77	T1/2	N+	8.7	CR
8	55	T3	N+	5.0	CR
9	68	T3	N+	4.9	CR
10	78	T3	N-	1.7	CR
11	55	T3	N+	4.7	CR
12	27	T3	N+	4.4	CR
13	26	T3	N+	0.8	CR
14	43	T3	N+	0.7	CR



Single centre study

No observed $\geq$ Grade 3 toxicity





Most Common AEs

	All Grades	Grade 3 or 4
Dermatologic -no.(%)		
Pruritus	6 (13)	0 (0)
Rash / dermatitis	10 (21)	0 (0)
Gastrointestinal-no.(%)		
Diarrhea	4 (9)	0 (0)
Nausea	4 (9)	0 (0)
Constitutional-no.(%)		
Fatigue	5 (11)	0 (0)
Fever	3 (6)	0 (0)
Endocrine-no.(%)		
Hypothyroidism	5 (11)	0 (0)

Patient #2

- SD / STABLE DISEASE
- PR / PARTIAL RESPONSE
- NCR / NEAR COMPLETE RESPONSE
- CR / COMPLETE RESPONSE




Patient #2

- SD / STABLE DISEASE
- PR / PARTIAL RESPONSE
- NCR / NEAR COMPLETE RESPONSE
- CR / COMPLETE RESPONSE




Patient #2

- SD / STABLE DISEASE
- PR / PARTIAL RESPONSE
- NCR / NEAR COMPLETE RESPONSE
- CR / COMPLETE RESPONSE



Patient #2

- SD / STABLE DISEASE
- PR / PARTIAL RESPONSE
- NCR / NEAR COMPLETE RESPONSE
- CR / COMPLETE RESPONSE




Conclusions

- 100% clinical complete response in all 42 patients who completed dostarlimab
- Clinical complete responses are durable over 2 years
- No patients have required chemotherapy, radiation or surgery
- AZUR1 Global confirmatory study of dostarlimab in dMMR rectal cancer is ongoing

AZUR-1

PD-1 blockade in dMMR locally advanced rectal cancer



N=30

Simon's two stage minimax

dMMR
<10% of rectal
cancer patients

Primary Objectives

- Overall response rate of PD-1 blockade with or without chemoradiation
- Pathologic complete response (pCR) or clinical complete response (cCR) rate at 12 months after PD-1 blockade with or without chemoradiation

Secondary Objective

- Safety and tolerability

AZUR-1

- **In July 2026** , the trial met its primary endpoint by achieving a durable rate of sustained cCR at 12 month
- This confirms that a significant portion of patients remained completely free of disease for 1 year
- Patients were able to avoid standard chemotherapy , radiotherapy and surgery

Sintilimab in MSI-H LARC

9




Figure 1: Treatment schema



	Patients (n=17)
Sex	
Female	6 (35%)
Male	11 (65%)
Median age, years	50 (35-59)
Lynch syndrome	6 (35%)
ECOG performance status score	
0	10 (59%)
1	7 (41%)
Clinical T stage	
T1-2	2 (12%)
T3	10 (59%)
T4	5 (29%)
Clinical N stage	
N0	3 (18%)
N+	14 (82%)
Mesorectal fascia positive	4 (24%)
Extramural vascular invasion	5 (29%)
Mismatch repair status	
MLH1 or PMS2 deficient, or both	7 (41%)
MSH2 or MSH6 deficient, or both	9 (53%)
Not available*	1 (6%)

Data are n (%) or median (IQR). Eastern Cooperative Oncology Group. * Confirmed as microsatellite instability-high status by PCR.

Table 1: Clinical characteristics of patients at baseline

Sintilimab in MSI-H LARC

10



CR (pCR or cCR) = 75%; 9 pts with cCR (no sx); 3/6 pts s/p sx with pCR

Chen, *Lancet GH* 2023

Toripalimab +/- Celecoxib in MSI-H Localized CRC




Figure 1: Study profile

	Toripalimab plus celecoxib group (n=17)*	Toripalimab monotherapy group (n=17)
Age at randomisation, years		
Median (IQR)	45 (35-58)	53 (45-60)
Range	23-69	31-69
Sex		
Female	8 (47%)	3 (18%)
Male	9 (53%)	14 (82%)
ECOG performance status		
0	7 (41%)	8 (47%)
1	10 (59%)	9 (53%)
Suspected Lynch syndrome†	4 (24%)	1 (6%)
Previously received neoadjuvant chemotherapy	4 (24%)	5 (29%)
Primary tumour location		
Ascending colon	5/19 (26%)	6 (35%)
Hepatic flexure	3/19 (16%)	3 (18%)
Transverse colon	4/19 (21%)	2 (12%)
Descending colon	0	1 (6%)
Sigmoid colon	3/19 (16%)	3 (18%)
Rectum	4/19 (21%)	2 (12%)
Clinical T stage		
T3	5/19 (26%)	1 (6%)
T4	14/19 (74%)	16 (94%)
Clinical N stage		
N0	3/19 (16%)	1 (6%)
N1	3/19 (16%)	4 (24%)
N2	13/19 (68%)	12 (71%)


Toripalimab +/- Celecoxib in MSI-H Localized CRC

14

	Toripalimab plus celecoxib group (n=17)*	Toripalimab monotherapy group (n=17)
Pathological complete response†	15 (88%; 95% CI 64-99)	11 (65%; 95% CI 38-86)
Major pathological response†	16 (94%; 95% CI 71-100)	17 (100%; 95% CI 81-100)
Pathological tumour regression		
0% viable tumour	18/19 (95%)	11 (65%)
1-10% viable tumour	0	6 (35%)
11-50% viable tumour	1/19 (5%)	0
51-100% viable tumour	0	0
Tumour regression grade		
0	18/19 (95%)	11 (65%)
1	0	2 (12%)
2	1/19 (5%)	4 (24%)
3	0	0
Pathological T stage		
ypT0	18/19 (95%)	11 (65%)
ypTis	0	2 (12%)
ypT1	0	1 (6%)
ypT2	0	1 (6%)
ypT3	1/19 (5%)	2 (12%)
Pathological N stage		
ypN0	18/19 (95%)	17 (100%)
ypN1	1/19 (5%)	0
Pathological disease stage		
ypTONOMO	17/19 (89%)	11 (65%)
ypTisNOMO-0	0	2 (12%)
ypT1NOMO-I	0	1 (6%)
ypT2NOMO-I	0	1 (6%)
ypT3N0-IIA	1/19 (5%)	2 (12%)
ypTONLaMO-IIIA	1/19 (5%)	0

Hu, Lancet Gastro Hep 2022

Study design



NCT04082572




FIG 1. CONSORT diagram. CR, complete response; PR, partial response; SD, stable disease.


TABLE 1. Baseline Patient Characteristics

Characteristic	No. (%)
Age at diagnosis, year	
Mean	57
Median (range)	62 (25-90)
Sex	
Female	15 (43)
Male	20 (57)
Race	
White	33 (94)
Other	2 (6)
ECOG PS	
0-1	33 (94)
2	2 (6)
Tumor types	
Colon adenocarcinoma	19 (54)
Rectal adenocarcinoma	8 (23)
Pancreatic adenocarcinoma	2 (6)
Duodenal adenocarcinoma	2 (6)
Other*	4 (11)
Clinical stage*	
II	8 (23)
III	26 (74)
Etiology of dMMR	
Sporadic	19 (54)
Lynch syndrome	16 (46)
Resectability	
Resectable	26 (74)
Unresectable	9 (26)
Prior therapy	
None	26 (74)
Radiation	4 (11)
Surgery	3 (9)
Chemotherapy	2 (6)

Neoadjuvant pembrolizumab yields high rates of pCR

- Median follow up: 9.5 months (range 0.8-17.5m)

Pathologic response rate in patients who received at least 3 cycles of pembro (13 of 15 surgical patients evaluable)




Pathologic response in all surgical patients (n=15)

Tumor	Stage	# cycles	Path stage
Colon	T4N0M0	8	T0N0(0/34LN)
Colon	T4N1M0	8	T0N0(0/122LN)
Colon	T4N1M0	14	T0N0(0/32LN)
Colon	T4N0M0	16	T0N0(0/13LN)
Colon	T4N1M0	8	T0N0(0/35LN)
Rectal	T3N1M0	11	T0N0(0/31LN)
Colon	T4N1M0	8	T0N0(0/27LN)
Colon	T4N1M0	8	T0N0(0/46LN)
Colon	T3NxM0	8	T0N0(0/24LN)
Colon	TxN1M0	1	T0N0(0/35LN)
Colon	T4N1M0	3	T0N1a(1/91LN)
Panc	T2N1M0	8	T1N1(3/37LN)
Panc	T3N0M0	5	T2N0(0/30LN)
Endometrial	IIIC	8	T1aN0(0/5LN)
Rectal	T3N1bM0	2	T4bN0(0/43LN)

Low rates of progression on neoadjuvant pembrolizumab

Swimmer plot of CRC (blue) and non-CRC patients (gray) showing duration of pembrolizumab (n =35)



- 4 patients completed 1 yr of pembro without surgery:
 - median f/u of 3 months (0,2,4,5 months)
 - no recurrences
- Reasons for surgery <6 months:
 - 1 month: clinical progression
 - 2 months: PR, colonic obstruction (pCR)
 - 3 months: PR, transaminitis (pCR)
- Endoscopic evaluation done in 22 of 28 luminal patients:
 - Complete endoscopic response in 12/22 (55%)
 - near complete response in 4/22 (18%)

Neoadjuvant treatment of dMMR colon cancers

Previous data from NICHE-1 ($n=32$) show that immune checkpoint blockade is highly effective in non-metastatic dMMR colon cancers

- 100% pathologic responses and 60% pathologic complete responses

ARTICLES


<https://doi.org/10.1016/j.natmed.2020.0805-6>

nature
medicine

Check for updates

Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers

Myriam Chalabi^{1,2,3,11}, Lorenzo F. Fanchi^{2,4,17}, Krijn K. Dijkstra^{2,4,17}, José G. Van den Berg^{2,17}, Arend G. Aalbers⁴, Karolina Sikorska⁷, Marta Lopez-Yurda¹⁸, Cecile Grootsholten¹, Geerard L. Beets^{4,9}, Petur Snaebjornsson¹, Monique Maas¹⁰, Marjolijn Mertz¹⁰, Vivien Veninga^{1,4}, Gergana Bounova^{4,10}, Annegien Broeks¹¹, Regina G. Beets-Tan^{9,10}, Thomas R. de Wijkerslooth¹, Anja U. van Lent¹⁴, Hendrik A. Marsman¹⁰, Elvira Nuijten⁷, Niels F. Kok⁸, Maria Kuiper¹, Wieke H. Verbeek¹, Marleen Kok^{1,10}, Monique E. Van Leerdam¹, Ton N. Schumacher^{1,4}, Emile E. Voest^{1,2,4,17,22} and John B. Haanen^{1,2,3,17}



PARIS
2022 ESMO congress


Myriam Chalabi, MD PhD

Content of this presentation is copyright and responsibility of the author. Permission is required for re-use.

Chalabi et. al, Nat Med 2020; Verschoor et. al, ASCO 2022

NICHE-2 study design

- Investigator-initiated, non-randomized multicenter* study



*6 participating hospitals in the Netherlands
PBMC = peripheral blood mononuclear cells


Baseline patient characteristics

Characteristic	Number at risk (%) of intention to treat population <i>n</i> = 112
Age, median (range)	60 (20-82)
ECOG performance status	
0	97 (87)
1	15 (13)
Female Sex	65 (58%)
Radiologic stage	
I/II	14 (13%)
Low risk III	15 (13%)
High risk III	83 (74%)
Primary tumor location	
Right colon	76 (68%)
Left colon	19 (17%)
Transverse colon	17 (15%)
Lynch syndrome	
Unknown	35 (31%)
	10 (9%)



Radiologic T stage	
T2	17 (15%)
T3 + T3/4a	25 (22%)
T4a	39 (35%)
T4b	31 (28%)
Radiologic N stage	
N0	14 (13%)
N1	29 (26%)
N2	69 (62%)
Radiologic high-risk with both T4 and N2	
	54 (48%)


Major pathologic response in 95% of patients; 67% pCR



Major pathologic response in 95% of patients; 67% pCR

Pathologic response (RVT)		Patients <i>n</i> = 107
Yes ($\leq 50\%$)	Major ($\leq 10\%$)	102 (95%)
	Complete (0%)	72 (67%)
	Partial (10% - 50%)	4 (4%)
	No ($\geq 50\%$)	1 (1%)

RVT = residual viable tumor



Adjuvant chemotherapy (CTx)

- 14 patients with ypN+ disease
- 3 patients received adjuvant CTx*
 - 5 patients >70 years
 - 6 patients refused

* 1 non-responder, 1 partial responder and 1 MPR

Disease recurrence


With a median follow-up of 13.1 months (1.4 - 57.4), there have been no disease recurrences

ility of the author. Permission is required for re-use.

pCR rate in Lynch vs sporadic tumors

	No pCR	pCR	
Sporadic tumor <i>n</i> = 65	27 (42%)	38 (58%)	p = 0.056
Lynch Syndrome <i>n</i> = 32	7 (22%)	25 (78%)	

N totals 97 patients in the per protocol population for whom Lynch status was available at data cut-off



Conclusions from NICHE2

- Only 4% grade 3-4 immune-related adverse events (amylase/lipase, hepatitis, myositis, rash)
 - Any AEs: 61%
- 100% R0 resections; 98% of patients underwent timely surgery (safety primary endpoint)
- 100% (32/32) of dMMR patients had response to nivo/ipi (69% pCR, 95% major pathologic responses)
 - Only 2 doses of nivo, 1 dose of ipi prior to surgery
- Potential for nonoperative management?
 - Colonoscopic surveillance, radiographic discordance, etc
- Biomarker studies, ctDNA dynamics eagerly awaited


Conclusions

- Imperative to test for MSI-H/dMMR in patients with localised rectal cancer at diagnosis
- Immunotherapy results in cCR in most of the patients
- Immunotherapy has the potential to spare patients from surgery , radiotherapy and chemotherapy
- Immunotherapy is tolerable



NCCN Guidelines Version 2.2025

dMMR/MSI-H Rectal Cancer





THANK YOU!